Navigation Links
CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
Date:8/18/2011

DURHAM, N.C., Aug. 18, 2011 /PRNewswire-iReach/ -- Durham, NC, August 18, 2011 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has received clearance to proceed with clinical studies of lasmiditan (formerly known as COL-144) under IND 103,420 from the Food and Drug Administration (FDA).

Lasmiditan is a first-in-class oral tablet formulation of a Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  Lasmiditan is a member of a novel chemical class called "ditans", and, unlike triptans, which target vasoconstrictor 5-HT1B receptors, lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Five clinical studies have been successfully completed outside of the U.S., including a Phase 2b double blind placebo controlled dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved numerous secondary endpoints per other migraine symptoms such as nausea, photophobia and phonophobia.  Importantly, lasmiditan's side effect profile is highly differentiated from triptans and ergotamines, and there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies.

"The migraine market, estimated at 30 million sufferers in the US, is an under-served market.  No new class of therapies has been introduced for the treatment of acute migraine since
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
2. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
3. Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
4. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
5. Access Pharmaceuticals Provides Second Quarter Update on MuGard Commercial Activities
6. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
7. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
8. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
9. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
10. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
11. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
...  -- Ametros Financial Corporation and Ringler Medicare Solutions, ... a partnership to offer Professional Administration services to ... and Life Care Planning services currently offered by ... http://photos.prnewswire.com/prnh/20120406/CG83519 ) Insurers, third-party administrators and ...
... Inc. , a clinical-stage epigenetics oncology company, announced Arthur ... "We are delighted to have Art Pappas ... a former senior level pharmaceutical executive and as a highly ... chairman of the Syndax board of directors.  "As Syndax ...
Cached Medicine Technology:Ametros Financial and Ringler Medicare Solutions Announce Partnership to Provide Professional Administration Services 2Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors 2
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... Improved Health Care Access and ... ... health care experience for patients and,practitioners alike, AT&T (NYSE: T ... deliver the country,s first statewide health,information exchange., The Tennessee Information ...
... Acuo Technologies is a market,leading provider of comprehensive ... collaboration and migration services. Recently,there has been an ... the,increasing size of digital imaging archives caused by ... onset of new contributors,like digital pathology systems. Many ...
... DELHI, Feb. 25, 2008 A vaginal microbicide that incorporates ... HIV is safe for sexually active HIV-negative women to use ... clinical trial of tenofovir topical gel. Moreover, most of the ... the United States adhered to a regimen involving either daily ...
... 25 Every Step Counts Organization in,association with ... Forest Park will continue its efforts to celebrate ... will host "Walk In,Her Shoes" 2008, a unique ... --,St. Louis and Atlanta. Designer shoes featured in ...
... Can Leverage WLAN Infrastructure to Improve Patient Care with Visibility ... ... Personnel, WALTHAM, Mass., Feb. 25 Colubris ... and,service providers, today announced that the company is working with,AeroScout, Inc., ...
... Wireless ECG Devices Help Healthcare Organizations Deliver Clinical ... Data Faster ... Colubris Networks, the leading,global provider of intelligent wireless LANs ... Science Corporation,(Nasdaq: CSCX ) ( http://www.cardiacscience.com ), the ...
Cached Medicine News:Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 2Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 3Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 4Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 5Health News:Acuo Technologies(R) Offers Free Migration Archive License 2Health News:Acuo Technologies(R) Offers Free Migration Archive License 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 2Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 4Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 5Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 6Health News:Shoe Therapy Helps Survivors Celebrate Life After Abuse 2Health News:Colubris Partners with AeroScout to Enable Real-time Location Detection over Wireless Networks 2Health News:Colubris Partners with AeroScout to Enable Real-time Location Detection over Wireless Networks 3Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: